Dapagliflozin alleviates renal fibrosis in type 2 diabetic mice through regulating STAT3
- 20 February 2026
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 248, 117833
Abstract
No abstract availableKeywords
Funding Information
- Key Research and Development Program of Liaoning Province (2024JH2/101900017)
- Shenyang Pharmaceutical University
- Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program (ZQN202201)
This publication has 28 references indexed in Scilit:
- Novel insights into STAT3 in renal diseasesBiomedicine & Pharmacotherapy, 2023
- Epithelial–mesenchymal plasticity in kidney fibrosisGenesis, 2023
- NQO1 alleviates renal fibrosis by inhibiting the TLR4/NF-κB and TGF-β/Smad signaling pathways in diabetic nephropathyCellular Signalling, 2023
- Mo3Se4 nanoparticle with ROS scavenging and multi-enzyme activity for the treatment of DSS-induced colitis in miceRedox Biology, 2022
- IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045Diabetes Research and Clinical Practice, 2022
- Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesisBiomedicine & Pharmacotherapy, 2021
- AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic miceCell Death & Disease, 2021
- Fuxin Granules ameliorate diabetic nephropathy in db/db mice through TGF-β1/Smad and VEGF/VEGFR2 signaling pathwaysBiomedicine & Pharmacotherapy, 2021
- Diabetic nephropathy: A twisted thread to unravelLife Sciences, 2021
- Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in STZ-induced diabetic miceCell Death & Disease, 2019